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Background: Oxidative stress, an excess of reactive oxygen species (ROS), causes lipid peroxidation resulting in
cell and tissue damages. It may be associated with the development and progression of cancers in dogs.
Malondialdehyde (MDA), the end product of lipid peroxidation, is commonly used as a marker of oxidative stress.
The objective of this study was to assess oxidative stress in cancer-bearing dogs by measuring serum MDA levels.
All client-owned dogs underwent physical examination at the Veterinary Teaching Hospital, Faculty of Veterinary
Medicine, Khon Kaen University to determine the health status with the owner’s consent. Blood samples of
cancer-bearing dogs (N = 80) and clinically normal dogs (N = 101) were obtained and subjected for determination
of MDA levels. In addition, complete blood count, creatinine, and alanine aminotransferase were measured.
Results: Serum MDA was significantly higher in cancer-bearing dogs than in clinically normal dogs (mean ± SD,
4.68 ± 1.32 μmol/L vs 2.95 ± 0.61 μmol/L, respectively; p < 0.001). Packed cell volume (mean ± SD, 36.18 ± 7.65% vs
44.84 ± 5.54%), hemoglobin (mean ± SD, 11.93 ± 2.88 g% vs 15.17 ± 2.00 g%) and red blood cells (median (IQA), 6.05
(2.15) vs 8.09 (1.34)) were all significantly lower in cancer-bearing dogs than in clinically normal dogs. However, the
reverse was true for white blood cells (median (IQA), 18.20 (11.95) vs 14.90 (5.10)). Neither creatinine nor alanine
aminotransferase levels were significantly different between groups.
Conclusions: This study supports the conclusion that oxidative stress is associated with many types of cancers in
dogs, as serum MDA levels were significantly higher in cancer-bearing dogs compared to clinically normal dogs.
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Oxidative stress is defined as an excess of reactive oxy-
gen species (ROS) due to an imbalance between the
rates of ROS production and ROS removal. Excess may
be caused by the overproduction of ROS, the reduction
of antioxidants that reduce ROS or both conditions [1].
ROS can seriously alter the structure of molecules such
as proteins, lipids, and deoxyribonucleic acid (DNA) [2].
These alterations may result in cell degeneration and
death causing aging [3], and play a significant role in the
pathogenesis of many diseases, such as cardiovascular
diseases, neuropathies, inflammatory diseases, acquired
immune deficiency syndrome (AIDS), diabetes mellitus,
renal diseases, and mammalian cancers [4-14]. In dogs,* Correspondence: patcha_b@kku.ac.th
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reproduction in any medium, provided the oroxidative stress has been associated with carcinogenesis
[15]. Cancer in dogs is a major cause of death [16-18]
and in Thailand there appears to be an increase in the
incidence of dog cancers, as the number of cancer-bearing
dogs diagnosed at the Veterinary Teaching Hospital, Khon
Kaen University, Thailand between January 2008 and
December 2011, increased by more than 50% (data from
the annual reports of the hospital).
Since oxidative stress triggers various antioxidant mech-
anisms in the body, biomarkers such as lipid peroxidation
products and endogenous enzymes with antioxidant prop-
erties have been identified and used to assess oxidative
stress in mammals [1]. Malondialdehyde (MDA), one of
the end products of lipid peroxidation has been widely
used as a biomarker of oxidative stress. MDA can be mea-
sured using several different assays; however, the simplest
and most common method is the thiobarbituric acid re-
active substances assay (TBARS) [19]. Although the useral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controversial, a study on dogs with mammary gland tu-
mors demonstrated that TBARS levels were significantly
higher in the tumor tissue than in the normal tissue [20].
In contrast, in two other studies, plasma MDA levels in
dogs with mammary tumors and with lymphomas did not
differ from those in control dogs [15,21]. Reports from
studies in humans indicated that serum and/or plasma
MDA levels were elevated in association with various
types of cancers (breast cancer [22,23], oral cancer [24],
and lung cancer [22,25]).
As there are few studies on oxidative stress in cancer-
bearing dogs compared to humans with cancer, the pri-
mary objective of this study was to evaluate oxidative
stress status in cancer-bearing dogs compared to clinic-
ally normal dogs by measuring MDA levels.
Methods
Animals
Client-owned dogs were enrolled in this study between
January 2010 and June 2011 at Veterinary Teaching
Hospital, Faculty of Veterinary Medicine, Khon Kaen
University, Khon Kaen, Thailand. Cancer-bearing dogs
had to be diagnosed with a malignant tumor by histopa-
thologists. The types of cancer were classified by evalu-
ation histopathological slides from a tissue biopsy. Dogs
undergoing chemotherapy or receiving antioxidant sup-
plements were excluded. Clinically normal dogs had to
be more than 2 years old without blood parasites or in-
testinal parasites and have had a normal physical exam-
ination at least 6 months before blood collection. Owner
consent was obtained for all participated dogs and the
study protocol was approved by The Research Ethics
Committee, Faculty of Veterinary Medicine, Khon Kaen
University.
Blood sample collection, preparation and analysis
Five mLs of blood was drawn from the cephalic vein and
divided into 2 parts. One mL was treated with ethylenedi-
amine tetraacetic acid (EDTA), an anticoagulant and used
to determine a complete blood cell count and the pres-
ence of blood parasites. The remainder was centrifuged at
3000 rpm at 4°C for 10 min to provide serum for blood
chemistry tests (e.g. creatinine and alanine aminotransfer-
ase (ALT) and MDA).
Packed cell volume (PCV), hemoglobin, red blood cell
counts (RBC) and white blood cell counts (WBC) were
measured by using an automatic analyzer (Sysmex XT-
2000iV, USA). Additionally, dried blood smears were fixed
in methyl alcohol and stained with Wright-Giemsa stain
and examined under oil immersion lens of the micro-
scope for parasites. Creatinine and ALT were measured
by using an automatic blood chemistry analyzer (Olympus
AU400, USA).Determination of malondialdehyde (MDA)
MDA concentrations were determined using serum sam-
ples kept at −80°C and the thiobarbituric acid reactive
substance assay (TBARS) [26,27]. One mL of serum di-
luted with normal saline, at a ratio of 1:1, was mixed
with 50 μL of 0.1 mmol/L butylated hydroxytoluene, 500
μL of 5 mmol/L EDTA, 1 mL of 8% sodium dodecyl
sulfate, 1 mL of 10% trichloroacetic acid and 1.5 mL of
0.67% thiobarbituric acid. The reaction mixture was in-
cubated at 95°C for 30 min and then centrifuged at
3000 rpm at room temperature for 15 min. The absorb-
ance of the supernatant was measured at 532 nm and
tetraethoxypropane was used to prepare a standard
curve at concentration ranges between 0.01- 0.2 μmol/L.
Statistical analysis
The normality of continuous data was assessed using
graphical display and the Shapiro-Wilk test. Data that
met the parametric assumptions, non-parametric data,
and categorical data were analyzed by an Independent
Sample t-test, Mann–Whitney U test and Pearson Chi-
square test, respectively. To account for the imbalance
in age between cancer-bearing dogs and clinically nor-
mal dogs, age was used as a covariate in an Analysis
of Covariance (ANCOVA) and an adjusted p-value was
obtained. To determine whether MDA levels differed
among cancer types, subgroup analysis was performed,
as the number of different cancer types found in this
study varied considerably. The less common cancers
(i.e., squamous cell carcinoma, melanoma, lymphoma,
adenocarcinoma, transmissible venereal tumor (malig-
nant), hemangiosarcoma, and angiosarcoma) were com-
bined and defined as “other cancers”. Data with normal
distributions were reported as means ± SD, but those
without normal distribution were reported as medians
(interquartile range). All statistical analyses were performed
by the statistical software (SPSS version 17; SPSS Inc.,
Chicago, Ill.) and values of p < 0.05 were considered
significant.
Results
Of the total 320 dogs, 107 were diagnosed with malig-
nant tumors and 213 were identified as clinically normal
dogs. Twenty-seven of the cancer-bearing dogs were ex-
cluded from the study, as they did not fulfill the inclu-
sion criteria. Hence, 80 cancer-bearing dogs were used
for final analysis. Of 213 clinically normal dogs, 112 dogs
were excluded because they did not fulfill the inclusion
criteria and therefore 101 clinically normal dogs were
used in this study.
Demographic characteristics of the cancer-bearing and
clinically normal dogs are shown in Table 1. Average age
in cancer-bearing dogs was significantly higher than that
in clinically normal dogs (mean ± SD, 9.06 ± 3.12 yrs vs
Table 1 Demographic characteristic of the cancer-bearing dogs and clinically normal dogs
Variables Cancer-bearing dogs Clinically normal dogs p-valuea
(N = 80) (N = 101)
Age, mean ± SD (range), yrs 9.06 ± 3.12 (2–15) 5.05 ± 2.20 (2–12) <0.001
Weight, mean ± SD (range), kg 20.20 ± 11.87 (4.2-49.2) 20.89 ± 9.24 (4.8-40.4) 0.663
Breed, no. (%) 0.003
Mixed 33 (41.25%) 65 (64.36%)
Pure breed 47 (58.75%) 36 (35.67%)
Sex, no. (%) 0.428
Male 26 (32.50%) 38 (37.62%)
Female 54 (67.50%) 63 (62.38%)
aAge and weight by Independent Sample t-test; breed by Chi-square test.
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was no significant difference in body weight between
groups (p = 0.663). The proportion of pure breeds in the
cancer-bearing dogs was significantly greater than that
in the clinically normal dogs (47/80 or 58.75% vs 36/101
or 35.67%, respectively; p = 0.0032). In the cancer-bearing
dogs, the pure breeds were Poodle (N = 10), Rottweiler (9),
Thai Ridgeback (7), Cocker Spaniel (5), Golden Retriever
(4), German Shepherd (2), Saint Bernard (2), Shih Tzu (2),
Chow Chow (1), Dalmatian (1), Labrador Retriever (1),
Miniature Pinscher (1), Pit Bull (1), and Siberian Husky
(1). In the clinically normal dogs, the pure breeds were
Golden Retriever (N = 8), Labrador Retriever (8), Thai
Ridgeback (8), German Shepherd (3), Cocker Spaniel (2),
Miniature Pinscher (1), Pit Bull (2), Pomeranian (1), Poo-
dle (1), Rottweiler (1), and Siberian Husky (1). Although
10 types of cancers were found in this study, the three
most common were mammary gland carcinoma (27/80 or
34%), mast cell tumor (15/80 or 19%), and osteosarcoma
(8/80 or 10%) (Table 2).
Serum MDA was significantly higher in cancer-bearing
dogs than in clinically normal dogs even with age adjusted
(mean ± SD, 4.68 ± 1.32 μmol/L vs 2.95 ± 0.61 μmol/L,Table 2 Number and percentage of dogs classified with
different cancer types
Cancer type Number of dogs (%)
Mammary gland carcinoma 27 (34%)
Mast cell tumors 15 (19%)
Osteosarcoma 8 (10%)





Malignant TVT 3 (4%)
Hemangiosarcoma 2 (3%)respectively; p < 0.001) (Table 3) and serum MDA did
not differ significantly among cancer types (p = 0.826)
(Figure 1).
The number of red blood cells and white blood cells in
both groups remain within normal ranges [28] (Table 3);
however, red blood cell counts were significantly lower in
cancer-bearing dogs than in clinically normal dogs (p <
0.001), whereas white blood cell counts were significantly
higher in cancer-bearing dogs (p < 0.001) (Table 3). No
blood parasites were found and creatinine and ALT lev-
els were within normal ranges and not significantly dif-
ferent between the two groups (p = 0.312 and p = 0.395,
respectively).
Discussion
As the design of this study is cross-sectional, the infer-
ence cannot be drawn that the oxidative stress causes
cancers or vice versa. Ideally, the best way to assess the
relationship between oxidative stress and ROS is to meas-
ure ROS directly. However, ROS are difficult to measure
with standard biochemical techniques due to their high
reactivity and short half-life. Therefore, surrogate markers
are required and MDA is commonly used as a biomarker
of oxidative stress for various pathological conditions and
diseases, including cancers [15,24,29,30].
In the present study, it was clear that MDA levels were
significantly higher in cancer-bearing dogs compared to
clinically normal dogs (Table 3). Moreover, MDA was sig-
nificantly higher in all cancer types studied in the subgroup
analysis (Figure 1). These results correspond to previous
studies on humans with breast cancer [22,23,29], oral can-
cer [24] and lung cancer [22,25]. However, controversy still
exists for the use of MDA as a biomarker for oxidative
stress in cancer-bearing dogs, because MDA values tend to
vary greatly among laboratories [15,23,24,29], which may
be related to the use of different types of MDA analyses
and/or experimental design [30].
A few studies report that MDA levels in dogs with mam-
mary gland tumors and lymphomas were not significantly
Table 3 Malondialdehyde, complete blood counts and blood chemistry parameters for cancer-bearing dogs and
clinically normal dogs
Variables Cancer-bearing dogs Clinically normal dogs p-valuea Adjusted p-valueb Normal ranges [28]
(N = 80) (N = 101)
MDA, mean ± SD, μmol/L 4.68 ± 1.32 2.95 ± 0.61 <0.001 <0.001
PCV, mean ± SD, % 36.18 ± 7.65 44.84 ± 5.54 <0.001 <0.001 37-55
Hemoglobin, mean ± SD, g% 11.93 ± 2.88 15.17 ± 2.00 <0.001 <0.001 12-18
RBC, median (IQA), 106/μL 6.05 (2.15) 8.09 (1.34) <0.001 NA 5.5-8.5
WBC, median (IQA), 103/μL 18.20 (11.95) 14.90 (5.10) <0.001 NA 6-17
Creatinine, median (IQA), mg/dL 0.90 (0.30) 1.00 (0.25) 0.312 NA 0.9-1.7
ALT, median (IQA), U/L 32.00 (33.00) 36.00 (26.00) 0.395 NA 10-120
Abbreviations: ALT alanine aminotransferase, MDA malondialdehyde, NA not applicable, PCV packed cell volume, IQA interquartile range, RBC red blood cells,
SD standard deviation, U/L unit per liter, WBC white blood cells.
aAn independent sample Students t-test was used for MDA, PCV, and hemoglobin, while a Mann–Whitney U test was used for RBC, WBC, creatinine, and ALT.
bAdjusted p-values were obtained from an analysis of covariance using the age of dogs as a covariate.
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studies on dogs with mammary tumors reported that
TBARS levels in tumor tissues were significantly higher
than those in the normal tissue [20] and concluded that
increased levels of MDA in dogs with pathological condi-
tions was associated with oxidative stress [31,32].
In the present study, the average age of dogs with cancer
(9 years old) was significantly greater than the control
group (5 years old) (Table 1), which potentially could ex-
plain differences in MDA levels. However, the correlation
analysis demonstrated that age was not correlated withFigure 1 Mean MDA levels in dogs with different cancer types and cl
significantly different and error bars indicate standard deviations.MDA levels in either cancer-bearing dogs or clinically nor-
mal dogs and MDA levels did not changed with age. To
further confirm that differences in age did not contribute
to differences in MDA levels, we did an additional ana-
lysis by excluding dogs aged 7 years or higher in both
groups. In this analysis, we found that age was not signifi-
cant different in either groups (mean ± SD, 4.43 ± 1.34 yrs
in cancer-bearing dogs (N = 14) vs 4.07 ± 1.33 yrs in clin-
ically normal dogs (N = 76)), but serum MDA levels were
still significantly higher in cancer-bearing dogs (mean ±
SD, 4.85 ± 1.62 μmol/L vs 2.92 ± 0.59 μmol/L, respectively;inically normal dogs. Means with the same letter (a or b) are not
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is due to an increase in free radicals with age and free
radical invasion of DNA over a long period. This results
in DNA damage, mutations, and possibly carcinogenesis
[33-36] and ultimately the loss of cell function and cell
death [37].
In this study, red blood cell counts in cancer-bearing
dogs were lower than those of healthy dogs, although they
remained within the normal range. As anemia is one of
the most common para-neoplastic syndromes [38,39] and
may develop with a malignancy through various mechan-
ism [40], we conclude that cancer-bearing dogs have ten-
dency to be anemic. In contrast, white blood cell counts
of cancer-bearing dogs were higher than those of healthy
dogs, which may be caused by tissue damage [41], inflam-
mation [42], oxidative stress [8], stress [43] and concomi-
tant infections [44] (Table 3).
Conclusions
In summary, this study supports the conclusions; (1) that
oxidative stress is associated with many types of cancers
in dogs, as serum MDA levels were significantly higher in
cancer-bearing dogs compared to clinically normal dogs,
(2) cancer-bearing dogs have a tendency towards anemia
with significant lower levels of PCV and hemoglobin, (3)
cancer-bearing dogs have elevated levels of white blood
cells.
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